Product Expansion Circulogene's move from liquid biopsy to tissue-based OncoGenDx and AI-driven LungLifeAI broadens the addressable oncology market. The one-tube, one-week turnaround and PD-L1 biomarker test offer a compelling value proposition for oncologists and pulmonologists, enabling cross-sell opportunities to labs, cancer centers, and radiology groups.

Channel Strategy The exclusive national launch of LungLifeAI via primary care channels signals a go-to-market push toward PCPs and IPN management programs. Target audiences include primary care networks, radiology practices evaluating IPNs, and community cancer programs, with potential upsell of liquid biopsy tests alongside AI tools.

Global Growth Active inquiries for Asia Pacific and Middle East markets, plus prior office expansion, point to international opportunities. Build region-specific partnerships with distributors, labs, and health systems to accelerate adoption of Circulogene’s liquid biopsy and tissue assays.

Clinical Value The platform combines somatic and germline analysis, blood/tissue/buccal sampling, and MSI/PD-L1 data to guide targeted therapies and monitoring. This differentiates Circulogene from competitors and can drive demand from oncologists, immunotherapy teams, and biotech partners seeking predictive biomarker tests and recurrence monitoring.

Tech & Partnerships A scalable tech stack with cloud infrastructure and e-commerce/CRM tools supports rapid deployment to large hospital systems and labs. This foundation enables data-driven selling, smoother integrations with lab information systems, and potential collaborations with CROs or diagnostic groups seeking scalable genomics capabilities.